Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.40 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.35 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.35 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.35 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.35 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.35 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.35 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.35 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.35 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20909687 | 0.83 | PKN2 (0.49) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL21672149 | 0.79 | PNMT (0.35) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL21941390 | 0.75 | NISCH (0.36) | PNMTCD44MAOBADRA2AADRA2B | |
| SCHEMBL12844664 | 0.71 | — | — | |
| SCHEMBL7959781 | 0.71 | ALDH1A1 (0.46) | — | |
| SCHEMBL29228916 | 0.71 | ALOX15 (0.41) | PNMTCD44MAOBADCY6ADCY3 | |
| SCHEMBL21040049 | 0.70 | ALDH1A1 (0.46) | — | |
| SCHEMBL21040048 | 0.70 | ALDH1A1 (0.46) | — | |
| SCHEMBL19706853 | 0.70 | ALDH1A1 (0.46) | — | |
| SCHEMBL21040050 | 0.70 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280023-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100280023-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280023-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, GPR6 | PNMT 2961/4885CD44 2269/4885MAOB 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.